Meet our team
Management with a proven track record
|
Prior to founding Montara, Drs. Hertz and Shokat previously collaborated to found Mitokinin, which advanced a potential first-in-class disease-modifying treatment for Parkinson's disease |
|
|
In October 2023, Mitokinin was acquired by AbbVie for $110 million upfront and up to $655 million in total deal value, in addition to tiered royalties |
|
|
Publications from the founding team include Nature, Cell, Science, Proceedings of the National Academy of Sciences, Nature Neuroscience, Journal of Biological Chemistry, and Neuron, among others |
Scientific advisory board with deep capabilities in neurodegeneration
|
Includes members of the National Academy of Sciences and Medicine, a Sjöberg Laureate, a Nobel Laureate, and an NIH New Innovator and Rainwater Prize recipient |
|
|
Inventors of “drugs for the undruggable,” such as KRAS and PINK1 |
|
|
Expertise in protein aggregation, synaptic transmission, synapse formation, and their importance in Alzheimer’s disease and neurodegeneration |
|
|
Pioneering work in functional genomic CRISPR screens in the relevant cell types for neurodegeneration, including neurons, astrocytes, and microglia |
We’re hiring. Find out how to join the Montara team
Management
Scientific Advisory Board
Chemistry and Development Advisors
Board of Directors
Investors
